{"id":"sinovac-pcv13","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by introducing inactivated pneumococcal antigens to the body, which triggers an immune response and helps the body produce antibodies to fight off the bacteria. This vaccine is designed to provide long-term protection against pneumococcal disease, including pneumonia, meningitis, and sepsis.","oneSentence":"Sinovac PCV13 is a vaccine that stimulates the body's immune response to protect against 13 serotypes of pneumococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:52.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F)"}]},"trialDetails":[{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sinovac PCV13","genericName":"Sinovac PCV13","companyName":"Sinovac Research and Development Co., Ltd.","companyId":"sinovac-research-and-development-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Sinovac PCV13 is a vaccine that stimulates the body's immune response to protect against 13 serotypes of pneumococcal disease. Used for Prevention of invasive pneumococcal disease caused by 13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}